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Abstract
Sesquiterpene lactones (SLs) are plant-derived compounds that display anti-cancer effects. Some SLs derivatives have a
marked killing effect on cancer cells and have therefore reached clinical trials. Little is known regarding the mechanism of
action of SLs. We studied the responses of human cancer cells exposed to various concentrations of dehydroleucodine
(DhL), a SL of the guaianolide group isolated and purified from Artemisia douglasiana (Besser), a medicinal herb that is
commonly used in Argentina. We demonstrate for the first time that treatment of cancer cells with DhL, promotes the
accumulation of DNA damage markers such as phosphorylation of ATM and focal organization of cH2AX and 53BP1. This
accumulation triggers cell senescence or apoptosis depending on the concentration of the DhL delivered to cells. Transient
DhL treatment also induces marked accumulation of senescent cells. Our findings help elucidate the mechanism whereby
DhL triggers cell cycle arrest and cell death and provide a basis for further exploration of the effects of DhL in in vivo cancer
treatment models.
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Introduction
Sesquiterpene lactones (SLs) are a large and structurally diverse
group of plant metabolites [1] many members of which display
anti-tumor effects [2,3]. The SLs of the guaianolide group are of
particular interesting as anti-tumor agents because each chemical
substitution to the guaianolide skeleton confers a particular
biological activity to the resulting compound [2].
Although our knowledge of the mechanism of action of SLs in
general is limited, some of them have reached clinical trials
because of an ability to selectively trigger cell death in cancer cells
while sparing normal cells [4–7]. The precise basis of this selective
effect is still unclear; however, many studies have demonstrated an
association between the anti-tumor effect of SLs and anti-
inflammatory responses [8–11]. There is recent evidence of an
intracellular cell killing effect triggered by SLs. The disruption of a
calcium pump in the endoplasmic reticulum [12,13], increased
generation in iron-dependent free radicals [14,15], control of
nuclear factor kB (NFkB), activation of the tumor suppressor p53
[8,16,17], alteration of the epigenetic code [18,19], and DNA
alkylation [20], have all been reported as target intracellular events
altered by SL treatment that could account for the anti-
tumorigenic effect of SLs [2]. Collectively, the above findings
indicate a potential multifactorial effect of SLs in cancer cells.
We study one particular lactone, dehydroleucodine (DhL), a SL
of the guaianolide group that consists of an alpha-methylene
butyrogamma-lactone ring connected to a seven-membered ring
that is fused to an exocyclic alpha, beta-unsaturated cyclopente-
none ring (structure: Fig. S1). The crystal structure of DhL was
recently resolved [21]. DhL can be isolated and purified at
concentrations .1% from the above-ground parts of Artemisia
douglasiana (Besser), a widespread and easily obtained medicinal
herb that is commonly used in Argentina [22]. We have shown
previously that DhL has an antiproliferative effect on plant cells,
rat cells [23,24], and mouse B16 melanoma cells, but not on
normal murine Melan-A melanocytes [25]. We have also found
that DhL inhibits the re-initiation of meiosis in amphibian oocytes
[26,27]. We therefore suspected that DhL might have anti-tumor
effects similar to those reported previously for other SLs of the
guaianolide group. We also thought that DhL could affect at least
certain aspects of the DNA damage response (DDR). Genotoxins
that are used for cancer treatment usually affect cellular
proliferation by increasing replication stress [28]. Alterations in
the coordinated replication process typically result in the
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accumulation of stalled, asymmetric, or broken replication forks
[29]. The defective activation of pathways that repair DNA lesions
generally triggers cell death programs (e.g., apoptosis), permanent
cell cycle withdrawal, or senescence [30].
In the present study, we confirmed the antiproliferative effect of
DhL in human cancer cells. Our analysis of the accumulation of
DNA damage markers revealed a striking correlation between the
extent of DNA damage and the activation of senescence and
apoptosis programs, which were selectively stimulated by lower
and higher DhL concentrations, respectively. Clonogenic assays
revealed the very effective depletion of proliferating cells by DhL-
induced apoptotic and senescence programs. Further analysis of
the novel role of DhL in cellular senescence showed that the
antiproliferative process was associated with a delay of the
progression through the G2 phase that preceded an arrest in the
following G1 phase. This phenomenon was accompanied by
reduced cyclin B1 levels and higher p53 levels, suggesting that p53
has the ability to promote cell cycle withdrawal. Transient DhL
treatment (8 h) was equally effective as continuous DhL treatment
in terms of the numbers of cells that displayed premature
senescence. Collectively, our findings indicate that DhL activates
different antiproliferative programs depending on the time frame
and on the concentration delivered to cells.
Materials and Methods
Reagents
Dehydroleucodine (DhL) (structure: Fig. S1) at 93% purity was
obtained as described in our previous study [21]. 49, 6-diamidino-
2-phenylindole (DAPI) was from Sigma-Aldrich (St. Louis, MO,
USA) and peroxidase-labeled streptavidin was from Dako Den-
mark S/A (Glostrup, Denmark). Antibodies against cyclin B1, p21,
p53 and anti-53BP1 were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Antibodies against beta-actin and biotin-
conjugated mouse monoclonal anti-digoxigenin were from Sig-
ma-Aldrich. Antibodies against phospho-Histone H2AX, phos-
pho-Histone H3 and phospho ATM were from Millipore,
(California), anti-phospho Chk1 wasfrom Cell Signaling Technol-
ogy, anti p53 (1801 and DO1) were gifts from Carol Prives-
Columbia University New York and anti p21 was from Santa
Cruz Biotechnology. Biotinylated anti-mouse antibody was from
Dako Denmark S/A. Cy3-conjugated anti-mouse secondary
antibody was from Jackson ImmunoResearch Inc. (West Grove,
PA, USA) and Alexa 488-conjugated anti-rabbit secondary
antibody was from Invitrogen/Life Technologies Corp. (Carlsbad,
CA, USA).
Cell Lines
Cell lines HeLa S3 (from human cervix carcinoma), MCF-7
(from human breast adenocarcinoma), WI-38 (from human
embryonic lung fibroblast) and WI-38 VA (from human embry-
onic lung SV 40 virus-transformed derivate of the WI-38 cell line)
were purchased from ATCC (Manassas, VA, USA) and cultured
for less than 6 months. HCT116 p53+/+ (clone 40.16) and
HCT116 p532/2 (clone 379.2) cells (from human rectal
carcinoma) [31] were generously donated by Dr. B. Vogelstein.
These cells were received from the Genetics Resource Core
Facility of the Johns Hopkins University School of Medicine
(Baltimore, MA, USA) in 2000. One vial of each sample was
amplified for 2 passages and frozen by Vanesa Gottifredi at
Columbia University (Manhattan, NY, USA). One of the vials
providing from Columbia University was thawed for use in the
present study in 2010. The number of passages did not exceed the
number of 20 or less upon the resuscitation in the year 2010. p53
levels were checked following each recovery. Cells were grown in
Dulbecco’s modified Eagle’s medium (D-MEM/F12, Gibco BRL,
Gaithersburg, MD, USA) supplemented with 10% fetal bovine
serum (FBS), 50 U/ml penicillin, and 50 mg/ml streptomycin in a
humidified incubator with 5% CO2 at 37uC. The cells were
harvested after reaching 70–80% confluence and were plated for
either subsequent passage or treatments.
Cell Synchronization and Treatments
HeLa cells were synchronized at the G1/S phases by a double
thymidine block as described by Knehr et al. [32]. Briefly, HeLa
cells (26105) were seeded in 6-well plates, treated with 4 mM
thymidine for 16 h, and released by treatment with regular
medium for 8 h. A second, synchronized arrest at the G1/S phases
was induced by further treatment of cells with 2 mM thymidine for
14 h (these cells are referred to hereafter as ‘‘synchronized cells’’).
In parallel experiments, HeLa, MCF-7, WI-38, WI-38 VA,
HCT116 p53+/+, and HCT116 p532/2 cells (26105) were
seeded in 6-well plates in D-MEM/F12 medium with 10% FBS
for 12 h (these cells are referred to hereafter as ‘‘unsynchronized
cells’’). Both synchronized and unsynchronized cells were released
by placement in fresh medium (D-MEM/F12 with 10% FBS)
containing DMSO or DhL (defined as time 0) and cultured for
various durations. DMSO was used as a vehicle control in all
experiments.
Cell Proliferation Assays
Synchronized or unsynchronized cells (26105) were treated with
various concentrations (0–30 mM) of DhL for 72 or 96 h. To
determine cell numbers, cells were trypsinized, suspended in
regular medium, and counted with a Neubauer chamber. For
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] assay, cells were washed with PBS and 2 ml serum-free
culture medium containing 1 mg/ml MTT (Sigma-Aldrich) was
added to each well. The medium was discarded after 4 h, DMSO
was added to dissolve MTT-derived formazan, and formazan was
quantified by the measurement of absorbance at wavelength
550 nm as described previously [33].
Apoptosis Assays
Apoptosis was assayed by TUNEL and by Annexin V
staining. For Tunel assay, it was used the ApopTag Plus in situ
detection kit (Oncor, Gaithersburg, MD, USA) as described
previously [34]. Briefly, cells cultured on coverslips were treated
with various concentrations (0–30 mM) of DhL for 24 or 48 h,
fixed with 4% paraformaldehyde in PBS for 30 min and post-
fixed with ethanol/acetic acid (2:1) for 5 min at 220uC.
Endogenous peroxidase activity was quenched by treatment
with 3% H2O2 in PBS for 5 min. The coverslips were treated
with 0.01 M citrate buffer (pH 3) to boiling in a microwave
oven for 30 min. Nucleotides were labeled according to the
manufacturer’s instructions. The coverslips were blocked with
10% bovine serum albumin (30 min at 20uC), incubated
overnight with biotin-conjugated mouse monoclonal anti-digox-
igenin antibody at 4uC, washed, incubated with biotinylated
anti-mouse antibody for 45 min at room temperature, washed
again, incubated with peroxidase-labeled streptavidin for 45 min
at room temperature, washed briefly with PBS, and incubated
with 0.5 mg/ml 3,39 diaminobenzidine tetrahydrochloride/
H2O2 for 10 min. The slides were lightly counterstained with
hematoxylin to reveal nuclei, examined and photographed with
a Nikon Eclipse E200 microscope (Nikon Corp., Tokyo, Japan).
The apoptotic index was calculated as the percentage of positive
nuclei based on an average of 100 cells in each experimental
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group in three independent experiments and expressed as %
apoptotic cells 6 SEM.
For the assessment of early stage apoptosis, cells were stained
with Annexin V [35] using the Annexin V-FITC fluorescence
detection kit (BD Biosciences San Jose, CA, USA) according to the
manufacturer’s instructions. Briefly, cells cultured on coverslips
were treated with various concentrations (0–30 mM) of DhL for
24, 48 or 72 h, washed with PBS twice and then once with
Annexin V Binding Buffer. The cells were stained with Annexin
V-FITC diluted 1:10 in Annexin V Binding Buffer for 15 min at
RT and fixed with 2% paraformaldehyde. The slides were
examined and photographed with a Nikon Eclipse TE 2000 U
motorized inverted microscope (Nikon Corp., Tokyo, Japan). The
apoptotic index was calculated as the percentage of cells stained
positive for Annexin V. 100 cells were counted in each
experimental group in three independent experiments and
expressed as % apoptotic cells 6 SEM.
Immunostaining and Microscopic Analysis
Cells were plated on 10-mm diameter coverslips, treated with
DhL after 24 h, fixed in 4% paraformaldehyde/sucrose for
20 min at room temperature, incubated with 0.1% Triton X-
100 for 15 min and blocked overnight in PBS/2% donkey serum
(Sigma-Aldrich). The coverslips were incubated for 1 h with
primary antibodies as below, washed and incubated for 1 h with
secondary antibodies conjugated to fluorophores. Whole nuclei
were visualized using DAPI. The primary antibodies used were
anti-cH2AX, anti-pH3 and anti-53BP1. The secondary antibodies
used were Cy3-conjugated anti-mouse and Alexa 488-conjugated
anti-rabbit. Images were obtained with a Zeiss Axioplan confocal
microscope or a Zeiss Axio Imager A2 (Carl Zeiss, Oberkochen,
Germany). 200 cells were counted for each time point in three
independent experiments.
Figure 1. DhL treatment inhibits cell proliferation in a dose-dependent manner. Unsynchronized HeLa (A) and MCF-7 cells (B) and
synchronized HeLa (C and D) cells were treated with 0, 5, 10, 20, or 30 mM DhL for 72 or 96 h and counted every 24 h. The total number of cells
counted each 24 h (Total cells) were compared with the number of viable cells (Viable cells) (D). Data are expressed as the mean 6 SEM of 3
independent experiments. (A), (B) and (C) * p#0.05, ** p#0.01, *** p#0.001 vs. control group (0 mM DhL). (D) * p#0.05, ** p#0.01, *** p#0.001 total
cells vs. viable cells.
doi:10.1371/journal.pone.0053168.g001
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Clonogenic Survival Assay
Synchronized HeLa cells (26105) were treated with various
concentrations (0–30 mM) of DhL for 48 h, trypsinized, suspended
in regular medium and counted. Viable cells (500/well) were
seeded in 6-well plates and cultured for 10 days until colonies were
large enough ($50 cells) to be clearly discerned. The medium was
then removed, and the cells were washed with PBS and fixed with
100% methanol for 30 min. The fixed colonies were stained with a
filtered solution of 0.5% (w/v) crystal violet (Sigma-Aldrich) for
10 min. The staining solution was removed, and the colonies were
scored manually. The clonogenic survival was expressed as a
percentage relative to the number of colonies formed in DMSO-
Figure 2. Treatment with 30 mM DhL induces apoptosis in HeLa cells. Unsynchronized (A) and synchronized (B) HeLa cells were treated with
0, 20, or 30 mM DhL for 24 or 48 h. DNA content was assessed by flow cytometry (see Fig. S2, DNA distributions). The percentages of unsynchronized
and synchronized cells in the sub-G1 phase are shown. (C) Synchronized HeLa cells were treated with 0, 20, or 30 mM DhL for 24 or 48 h. Apoptotic
cells were assessed by TUNEL assay. Left: representative panels with apoptotic cells indicated by arrowheads. Bar: 50 mm. Right: percentages of
apoptotic cells at 24 and 48 h. (D) Unsynchronized HeLa cells were treated as in (C) and subjected to Annexin V assay. Left: representative panels with
apoptotic cells stained with Annexin V (bright cells) at 24 h. Representative fields of Annexin V positive cells for 48 and 72 h treatment are shown in
Fig. S2 C. Bar: 50 mm. Right: percentages of apoptotic cells at 24, 48 and 72 h. Data represent mean 6 SEM of 3 independent experiments. * p#0.05,
** p#0.01, *** p#0.001 vs. control group (0 mM DhL).
doi:10.1371/journal.pone.0053168.g002
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Figure 3. DhL treatment causes the accumulation of DNA damage markers. Unsynchronized HeLa cells were treated with 0, 20, or 30 mM
DhL and lysed or fixed at the indicated times. (A) Immunoblot analysis of phospho-ATM (p-ATM) and phospho-Chk1 (p-Chk1). Representative assay of
3 independent experiments. b-actin was employed as a loading control. Cells were stained with DAPI to visualize the nuclei and treated with specific
antibodies for cH2AX (B) and 53BP1 (C). Left: representative fields from 24 h treatment. Insets: magnification of the areas indicated by boxes in the
top row. Representative fields for 48 h treatment are shown in Fig. S3. Right: quantification of the number of cells with more than 10 cH2AX foci and
more than 5 53BP1 foci. At least 200 nuclei were scored for each sample. Bar: 10 mm. Data represent mean 6 SEM of 3 independent experiments. *
p#0.05, ** p#0.01 vs. control group (0 mM DhL).
doi:10.1371/journal.pone.0053168.g003
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Figure 4. DhL delays mitosis entry extends the permanence of mitosis, and downregulates cyclin B1. Synchronized HeLa cells were
treated with 0, 10, or 20 mM DhL and analyzed by phase contrast in live time-lapse microscopy from 0 to 32 h treatment; images were acquired every
15 min using a Nikon Eclipse TE 2000-U microscope. (A) Representative images of cells at the beginning of treatment (T = 0), prophase, metaphase,
anaphase, telophase, and cytokinesis. Upper right of each panel: average time (h:min) to reach each phase. Bar: 20 mm. The average times of mitosis
and cytokinesis (B) and of the phases of mitosis (C) were calculated by analyzing 4 movies following 200 cells for each treatment. (D) Immunoblot
analysis of cyclin B1. Left: immunoblot representative of 3 independent experiments. b-actin was employed as a loading control. Right: mean
intensity 6 SEM obtained from densitometric analysis of 3 independent experiments. * p#0.05, ** p#0.01 vs. control group (0 mM DhL).
doi:10.1371/journal.pone.0053168.g004
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Figure 5. 20 mM DhL inhibits cell growth by inducing transient arrest in the G2/M phase and permanent accumulation in the G1
phase. (A) Synchronized HeLa cells were treated with 0–20 mM DhL for 72 h and subjected to DNA flow cytometry at indicated times. Representative
DNA distributions from one experiment are shown. (B) Percentage of cells in G1 (left panel), S (middle panel), and G2/M (right panel) phases were
determined using the WinMDI 2.9 program. (C) Left: unsynchronized HeLa cells were treated with 0–20 mM DhL and stained with DAPI (to visualize
nuclei) and antibodies specific to phospho-H3 at the indicated times. Right: percentage of phospho-H3 positive cells. Bar: 10 mm. (D) Cells were
treated with the indicated concentrations of DhL for 48 h, counted, and replated after treatment. Cells that had the ability to form colonies were
scored based on clonogenic survival assay 10 days post-treatment. Left: fixed and stained colonies from each treatment representative of 3
independent experiments. Right: number of colonies counted expressed as a percentage of the control (defined as 100%). Data represent mean 6
SEM of 3 independent experiments. * p#0.05, ** p#0.01, *** p#0.001 vs. control group (0 mM DhL).
doi:10.1371/journal.pone.0053168.g005
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treated cells (control). Assays were performed in triplicate for each
DhL concentration and time period.
Cell Cycle Analysis
Cell DNA content was determined by flow cytometry.
Following treatment, cells were washed with PBS, trypsinized,
pelleted by centrifugation at 3,000 rpm for 5 min and fixed with
70% ethanol (20 min, 220uC). The fixed samples were incubated
with 50 mg/ml propidium iodide and 0.1 mg/ml RNase and then
analyzed on a flow cytometer (BD FASCanto II, Becton
Dickinson, Franklin Lakes, NJ, USA). A total of 16104 events
were analyzed using the WINMDI 2.8 software program (Joe
Trotter, WinMDI, Scripps Institute, La Jolla, CA, USA; http://
fac.-scripps.edu). Histograms were analyzed using the Cylchred
program (Terry Hoy, Cylchred, Cardiff University, UK; http://
cardiff.acuk).
Live Cell Time-lapse Microscopy and Analysis
Phase-contrast time-lapse microscopy was performed on syn-
chronized HeLa cells treated with various concentrations (0–
20 mM) of DhL. Following the removal of the second thymidine
block, 100 independent cells for each condition were recorded
using a Nikon Eclipse TE 2000 U motorized inverted microscope
(Nikon Corp., Tokyo, Japan) with an incubation chamber (37uC,
5% CO2) and a Hamamatsu ORCA-ER cooled CCD camera
(Hamamatsu Photonics, Tokyo, Japan). Time-lapse videos were
reviewed and the timing of the various phases of mitosis was
determined using the Image J software program (Rasband WS,
Image J. Bethesda, MD: National Institutes of Health: 28 October,
2003. http://rsbweb.nih.gov/ij/).
Gel Electrophoresis and Western Blot Analysis
Treated cells were washed twice with ice-cold PBS, pelleted and
lysed by freeze/thaw in extraction buffer (50 mM HEPES,
pH 7.5, 1 mM EDTA, 150 mM NaCl, 10 mM b-glycerophos-
phate, 1 mM NaF, 0.1% Triton X-100, 10% glycerol, with
protease inhibitors) for 30 min on ice. The samples were
centrifuged at 12,000 rpm for 20 min at 4uC and supernatants
were collected. Protein concentrations were determined by the
Bradford method [36]. Cell extracts were separated by SDS-
PAGE and transferred onto nitrocellulose membranes (BioRad
Laboratories, Hercules, CA, USA). The membranes were
incubated with antibodies against cyclin B1, p21, p53 and b-actin
for 2 h at room temperature and overnight at 4uC with antibodies
against phospho-ATM and phospho-Chk1. Subsequently, mem-
branes were incubated with the appropriate horseradish peroxi-
dase-conjugated secondary antibodies. A SuperSignal West Pico
chemiluminescent substrate kit (Pierce/ThermoFisher Scientific
Inc., Rockford, IL, USA) was used to visualize protein bands.
Band densities were determined using the Image J program.
Senescence-associated b-galactosidase Assays
Senescence-associated b-galactosidase (SA-b-Gal) activity was
monitored in cell extracts and in situ. Soluble SA-b-Gal levels in
cell extracts were determined as described by Lee et al. [37].
Briefly, equal numbers of cells were collected for untreated or
treated conditions, washed, resuspended in extraction buffer and
lysed by freeze/thaw. The samples were centrifuged at 12,0006g
for 10 min, and the resulting supernatants were mixed with
2.2 mg/ml 1,4-methyl-umbelliferon-b-D-galactopyranoside (Sig-
ma-Aldrich) in 1 mM MgCl2 phosphate buffer, pH 6 and
incubated at 37uC for 2 h. The reaction was terminated by
addition of two volumes of 1 M sodium carbonate. SA-b-Gal
activity was monitored by measuring fluorescence emission at
360–448 nm with an Aminco Bowmen II Spectrophotofluorom-
eter (American Instrument Co., Silver Spring, MD, USA). Protein
concentrations were determined by the Bradford method.
In situ SA-b-Gal staining was performed as described by Dimri
et al. [38]. Briefly, cells were fixed with 2% formaldehyde and
0.2% glutaraldehyde for 5 min and incubated overnight at 37uC
with 1 mg/ml X-gal staining solution (5-bromo-4-chloro-3-indolyl
b-D-galactoside, 5 mM K3Fe[CN]6, 5 mM K4Fe[CN]6, and
2 mM MgCl2 in PBS, pH 6.0). The cells were rinsed twice with
PBS, washed with methanol and examined using a Nikon Eclipse
E200 microscope (Nikon Corp., Tokyo, Japan).
Senescence-associated Heterochromatin Foci (SAHF)
Assay
Cells grown on chamber slides were fixed with 2% parafor-
maldehyde for 30 min, washed with PBS, incubated with 0.2%
Triton X-100 in PBS for 1 h, washed with PBS and incubated
with PBS containing 1 mg/ml DAPI at room temperature for
5 min. The number of cells in SAHF assay was determined using a
confocal microscope (Olympus FV-1000; Olympus, Tokyo, Japan)
with an excitation wavelength of 350 nm. A total of 100 cells were
analyzed for each time point in two independent experiments.
Statistical Analysis
The data shown are mean 6 SEM from 2 or 3 independent
experiments. Statistical analyses were performed using one-way
ANOVA or paired two-tailed Student’s t-test (Prism 5 program,
GraphPad Software Inc., La Jolla, CA, USA). Differences were
considered significant for p values #0.05.
Results
DhL Inhibits the Proliferation of Human Cancer Cells
To investigate the effects of DhL on human cancer cells, we first
examined its effects on cell proliferation. HeLa and MCF-7 cells
were treated with various concentrations of DhL for 72 h, and the
effect on cell growth was evaluated by cell counting. The half
maximal inhibitory concentration (IC50) of DhL at 72 h culture
for HeLa cells was 10 mM (Fig. 1A). The cell number further
decreased to 80% when 20 mM DhL was used. The IC50 of DhL
at 72 h culture for MCF-7 cells was 5 mM (Fig. 1B). Similar effects
were observed when DhL was added to synchronized HeLa cells
and cell proliferation was assessed by cell count (Fig. 1C) or by
MTT assay (Fig. 1D). The estimation of the number of total cells
Figure 6. p53 sensitizes cells to the antiproliferative effect of DhL. (A) Synchronized HeLa cells treated with 0–20 mM of DhL were lysed at
the indicated times. Immunoblot analyses of proteins p53 and its transcriptional target p21 are shown. Lower plots: densitometric analysis of p21 and
p53 normalized to b-actin. Relative intensities of the bands are expressing percentages relative to the control (defined as 100%). The immunoblots
shown are representative of 3 independent experiments with similar result. * p#0.05, ** p#0.01 *** p#0.001 for the treated group (20 mM DhL) vs.
control group (0 mM DhL). (B) Unsynchronized HCT116 p53+/+ and HCT116 p532/2 cells were treated with 0, 5, 10, or 20 mM DhL, lysed at the
indicate times and proteins p53 and p21 were analyzed by immunoblot. b-actin was employed as a loading control (upper panel) or counted at the
indicated times (lower panel). The immunoblot shown are representative of 3 independent experiments with similar result. Data represent the mean
6 SEM of 3 experiments, * p#0.05, ** p#0.01 for HCT116 p53+/+ vs. HCT116 p532/2.
doi:10.1371/journal.pone.0053168.g006
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Figure 7. DhL induces cellular senescence in HeLa cells. Synchronized HeLa cells treated with 0–20 mM DhL for 48 h were analyzed for: (A)
protein concentration and (B) SA-b-Gal activity (at pH 6) in cell extracts. Equal volumes of supernatants were assayed. C) SA-b-Gal activity at pH 6 in
situ. Representative panels for control and treated cells stained for SA-b-Gal and examined by bright field microscopy are shown. Bar: 50 mm. Right:
percentages of SA-b-Gal-positive cells. (D) Senescence-associated heterochromatin foci (SAHF) in control and treated cells stained with DAPI and
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and the number of viable cells each 24 h indicated that during
96 h of DhL treatments, only 30 mM DhL affected the viability of
the cells (Fig. 1D).
In order to asses if DhL inhibition of proliferation is selective of
cancer cells, we performed cell counting experiments on normal
WI-38 lung fibroblasts and transformed WI-38 VA cells. The IC50
of DhL at 72 h culture was 4 mM for WI-38 cells and 14 mM for
WI-38 VA cells (Fig. S1B) showing that WI-38 VA cells are more
sensitive to DhL treatment. While a cell line-dependent drug effect
cannot be ruled out, these findings indicated that the proliferation
of several tumor cell lines is inhibited by DhL in a dose-dependent
manner.
DhL does not Induce Massive Apoptosis at 20 mM
Concentration
The reduction in cell number upon DhL addition could result
from cell death, cell cycle arrest or both. We initially evaluated the
extent of cell death induced by DhL treatment. Because high doses
of DhL clearly reduced cell proliferation in both cell lines and in
both proliferation assays (Fig. 1), we analyzed the distribution of
HeLa cells at various cell cycle stages following treatment with 20
and 30 mM DhL. Signals of cell death in terms of the presence of a
sub-G1 phase increased only weakly when cells were incubated
with 20 mM DhL. In striking contrast, a massive increase in the
sub-G1 phase population was observed when cells were treated
with 30 mM DhL (Figs. 2A and S2A). Similar results were obtained
when HeLa cells that were synchronized in the G1/S phase were
released in growth medium containing DhL (Figs. 2B and S2B).
These findings indicate that HeLa cell death was specifically
upregulated when the DhL dose was 30 mM.
To determine whether the cell death induced by DhL was
apoptotic, we used the specific TUNEL assay. A DhL concentra-
tion of 20 mM induced only a slight increase in the TUNEL signal
(i.e., the percentage of cells with TUNEL-positive DNA) following
24 or 48 h of treatment, whereas a DhL concentration of 30 mM
caused a considerable increase in the TUNEL signal (Fig. 2C).
Similar results were obtained when scoring for Anexin V positive
cells (Fig. 2D and S2C). These findings indicate that a high DhL
concentration promoted the apoptotic death of HeLa cells whereas
a lower concentration reduces cell number without causing an
increase in death markers.
Since cell death and apoptosis can result from the activation of
checkpoint kinases involved in the activation of the DDR response
we analyzed the effect on DhL in the phosphorylation/activation
of checkpoint kinases ATM and Chk1. We observed that ATM,
but not Chk1, was phosphorylated by treatment with all
concentrations of DhL reaching maximal phosphorylation at 8 h
of treatment (Figs. 3A and S3A). We then analyzed the levels of
histone H2AX phosphorylation, which is associated with the
activation of checkpoint kinases in the chromatin microenviron-
ment surrounding damaged DNA [39]. DhL concentrations of 20
and 30 mM (but not 10 mM) induced the accumulation of
phosphorylated H2AX (cH2AX) foci at 24 h (Fig. 3B), indicating
that both the antiproliferative and the apoptotic effect of DhL
were associated with the accumulation of damaged DNA. A
reduction in the number of cells with cH2AX foci was observed
following 48 h treatment with 20 mM DhL (Figs. 3B and S3B). In
contrast, no reduction in this parameter was observed following
48 h treatment with 30 mM DhL (Figs. 3B and S3B), suggesting
that increased amounts of irreversible DNA damage may be
associated with the increased apoptosis triggered by the higher
(30 mM) DhL concentration.
Replication-associated irreversible errors have been linked with
the accumulation of double strand breaks (DSBs). ATM activation
has also been linked to DSBs accumulation. DSBs are the most
deleterious type of DNA lesion and may have severe consequences
for cell survival if left unrepaired [40]. We analyzed the subnuclear
organization of 53BP1, a well-established DSB marker [41]. DhL
concentrations of both 20 and 30 mM increased the number of
53BP1-positive HeLa cells at 24 and 48 h of treatment (Figs. 3C
and S3C), with the 30 mM concentration being the stronger
inducer of 53BP1 focal accumulation (Fig. 3C). Collectively, these
findings indicate that DhL might cause accumulation of DNA
lesions that trigger the activation of ATM and downstream
markers of DDR response.
DhL Causes a Transient Arrest in the G2/M Phase
Followed by Cell Accumulation in the G1 Phase of the
Following Cycle
In view of the observation that 20 mM DhL caused the
accumulation of DNA damage, we examined the mechanism
whereby this DhL concentration caused an apoptosis-independent
reduction in cell number. To determine initially whether DhL
caused transient or permanent delays in any phase of the cell cycle,
we examined synchronized HeLa cells by live time-lapse
microscopy and compared the kinetics of mitosis entrance and
exit in control (mock-treated) and DhL-treated cells. There was a
significant increase in the timing of mitosis entrance in DhL-
treated cells. Control cells entered mitosis at 11.760.5 h, whereas
cells treated with 10 or 20 mM DhL entered mitosis at 16.061.7 h
or 16.260.5 h, respectively (Fig. 4A). The time that cells spent in
mitosis was also altered by DhL treatment. Control cells spent an
average of 1.960.1 h in mitosis, whereas DhL-treated cells
remained in mitosis an average of 4.8 h longer (Fig. 4B). This
delayed transition through mitosis was observed mainly at
metaphase-telophase (Fig. 4C). The treated cells spent 1.4 h
longer in cytokinesis that did control cells (Fig. 4B). In view of the
striking delay in the G2/M phase caused by DhL treatment, we
evaluated the levels of cyclin B1, a key factor that positively
modulates the G2/M transition [42]. The concentration of cyclin
B1 was significantly lower in treated cells, consistently with the
slow progression through the G2/M phase (Fig. 4D). This finding
provided molecular evidence for the inhibitory role of DhL in G2/
M progression.
We examined the possibility that defects associated with DhL
treatment had an irreversible impact on the cell cycle. Synchro-
nized HeLa cells were released in culture media containing either
DMSO or 20 mM DhL, and the cell cycle distribution at various
time points was evaluated by flow cytometric analysis. A clear
delay in the transition through the first S and G2/M phase was
observed within the first 12 h in DhL-treated cells (Fig. 5A, B). At
24, 48 and 72 h, while DhL-treated cells accumulated in the
examined by bright field and fluorescence microscopy (merge: bright field/DAPI) and fluorescence microscopy (DAPI). The insets are magnifications
of the boxed areas in the DAPI column. Arrowheads indicate the SAHF. Bar: 10 mm. Right: percentages of SAHF-positive cells. (E) Synchronized HeLa
cells treated with 20 mM DhL and then with fresh medium plus DMSO (‘‘Fresh medium’’) for the time indicated in the upper panel (treatment 1–4) or
with fresh medium for 24 h (treatment 5) were analyzed for protein concentration and for SA-b-Gal activity at pH 6. The protein concentration (lower
left) and SA-b-Gal activity (lower right) in cell extracts from each treatment are shown. Equal volumes of extract were assayed. Data represents the
mean 6 SEM of 2 experiments. * p#0.05, ** p#0.01, *** p#0.001 vs. control group (0 mM).
doi:10.1371/journal.pone.0053168.g007
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following G1 phase, control cells were transitioning through not
only the G1 phase but also the following S phase (Fig. 5A, B).
These findings indicated that cell cycle progression was delayed in
the treated cells.
We analyzed the phosphorylation of histone H3 in asynchro-
nous populations of DhL-treated HeLa cells and found an increase
in the number of cells that scored positive for this M-phase marker
(Fig. 5C, 16 h time point). This finding suggested that cells
undergoing the first G2/M phase transition following DhL
treatment experienced longer, transient stops in the G2 and M
phases that control cell populations (see decay at later time points
in Fig. 5C).
The alteration of transitions through the cell cycle phases and
the strong accumulation of DDR markers caused by 20 mM DhL
suggested that this concentration triggered a prolonged cell cycle
arrest at the G1 phase. We considered the possibility that, despite
the lack of apoptotic response to treatment with 20 mM DhL, a
permanent arrest in G1 phase may have reduced the colony-
forming ability of HeLa cells. We observed a reduction in colony
formation in cells that were replated following treatment with
30 mM DhL. Treatment with 20 mM DhL significantly reduced
the number of colonies (Fig. 5D) despite its modest effect on
apoptosis (Fig. 2). Collectively, these findings suggest that
treatment with 20 mM DhL may cause permanent withdrawal
from the cell cycle.
The p53-p21 Pathway is Upregulated by DhL
The permanent cell cycle arrest of HeLa cells following
20 mM DhL treatment suggested that antiproliferative signals
may be upregulated by DhL. Furthermore, our observations
regarding the effect of DhL on cH2AX and 53BP1 accumu-
lation indicated that targets of the ATR/ATM-Chk kinase
pathway might be activated [43]. One of the most studied
effector molecules of the checkpoint pathway is the tumor
suppressor p53, which is a universal target of genotoxins. We
therefore examined the possible alteration of p53 activity by
DhL treatment. We observed increased p21 levels following
DhL treatment at all times tested (Fig. 6A), consistently with our
results for G1 phase accumulation (Fig. 5A, B). We also found a
transient increase of p53 up to 16 h (Fig. 6A). Because the
accumulation of p53 is generally associated with the activation
of checkpoint signal proteins, we inferred that DNA damage
caused by DhL treatment could trigger p53 accumulation and
activation.
Finally, we considered the possibility that activation of the p53
signaling pathway played a role in the antiproliferative effect of
DhL. We used HCT116 p53+/+ cells and their isogenic derivative
HCT116 p532/2 cells [44] to test this idea. First, we evaluated
the effect of DhL on the accumulation of the p53 target, p21 and
we observed a much more evident accumulation of p21 in
HCT116 p53+/+ which suggested that DhL cause p53 transcrip-
tional activation (Figs. 6B upper immunoblot panels and S4A).
Furthermore, DhL had a clear antiproliferative effect on both cell
lines, but the effect was stronger on the HCT116 p53+/+ cells,
particularly at DhL concentrations below 20 mM (Fig. 6B lower
panels). In fact, MCF-7 (Fig.1) and HCT116 cells (this figure), both
express wild type p53, and are more sensitive than HCT116
p532/2 or even HeLa cells to the growth suppressive effects of
DhL at concentrations below 20 mM. These findings indicate that
p53 partially mediates the antiproliferative effect of low concen-
trations of DhL.
DhL Induces Premature Senescence
The permanent arrest in the G1 phase mediated by p53 has
been linked in most cases with DNA damage-induced senescence
[44]. We considered the possibility that DhL promotes senescence
in HeLa cells. Bulk protein concentration has been found to
increase in senescent cells [45]. We therefore measured the protein
concentration and monitored the enzymatic activity of SA-b-Gal
in HeLa cell extracts at 24 and 48 h following DhL treatment.
Both of these senescence parameters showed increases following
treatment with 20 mM DhL (Fig. 7A, B). Consistently with this
finding, we observed that DhL-treated cells were larger and flatter
than control cells and showed a striking increase in the number of
cells that stained positive for SA-b-Gal activity in situ (Fig. 7C).
Previous studies have shown that heterochromatin in senescent
cells is organized into foci (SAHF) that are not observed in cycling
cells [46]. We observed a marked increase of cells with SAHF
following DhL treatment (Fig. 7D). Collectively, the above findings
suggest that the apoptosis-free antiproliferative effect of 20 mM
DhL is associated with premature senescence.
p53 transcriptional activity was linked previously to the onset of
the senescence process [47]. We evaluated the contribution of p53
to the upregulation of senescence using a 10 mM concentration of
DhL. This low concentration inhibited proliferation more
efficiently in HCT116 p53+/+ cells than in HCT116 p532/2
cells (Fig. 6B lower panels). In senescence assays using 10 mM DhL
we observed senescent cell percentages of 64% in HCT116 p53+/
+ cells but only 38% in HCT116 p532/2 cells (Fig. S4B). Since
we observed detectable senescence in HCT116 p532/2 cells and
HeLa (cells that might have a down modulated p53 pathway), this
finding supports the idea that p53 might partially contribute to the
senescent effect of DhL.
Transient Incubation with DhL Promotes Senescence in
HeLa Cells
Partially in view of the potential application of DhL in the
treatment of patients, we examined the degree of senescence
caused by short-term exposure of HeLa cells to DhL using an
experimental protocol in which senescence markers were moni-
tored in cells treated with DhL for various durations. Following the
treatment, DhL was removed by washing and the cells were
incubated with fresh medium for a total of 24 h of culture (Fig. 7E,
upper panel). The increase in protein concentration and SA-b-Gal
accumulation for cells incubated with 20 mM DhL for 8 h followed
by 16 h incubation without DhL was the same as for cells
incubated continuously with DhL for 24 h (Fig. 7E). This finding
suggests that DhL is a powerful antiproliferative agent even when
administered for a limited duration. This effect should be further
explored in mouse models of cancer treatment.
Discussion
The results of this study show that the reduced proliferation of
cancer cells treated with DhL is accompanied by increased focal
organization of DNA-damage sensors (c-H2AX and 53BP1) and
increased levels and activity of p53. We therefore infer that DhL
triggers at least certain aspects of the DDR response [41], which in
turn activates apoptotic and senescence programs that are closely
associated with the levels of DNA damage [30]. A permanent
arrest of the G1 phase can be activated by not only low DhL
concentrations but also transient exposure to DhL.
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The Accumulation of DNA Damage and the Cellular
Response to DhL
Our findings suggest that the choice between apoptosis and
senescence in DhL-treated HeLa cells is linked to the amount of
DNA damage caused by DhL. Our analysis of cH2AX foci
assembly showed that an apoptosis-inducing concentration of DhL
caused a higher and more sustained accumulation of this marker
(Fig. 3B, 48 h time point). The apoptosis induced by 30 mM DhL
might be preceded by a failure of cells with high levels of damaged
DNA to progress normally through the cell cycle (Fig. S2A, B
FACS analysis). This cell death may in turn result in the excessive
collapse of replication forks and sustained accumulation of DSBs
[40]. We can infer the latter from the increase of phosphorylated
ATM at 8 hours of DhL treatment and the accumulation of DSB
markers (such as the 53BP1 foci assembly) that are detected at all
time points following treatment with 30 mM DhL (Fig. 3C). The
cell death observed following this treatment may result from a
failure to correctly replicate DNA in the cells that are transitioning
through the S phase. The reduced but still detectable levels of
DNA damage (indicated by the analysis of phospho-ATM,
cH2AX and 53BP1 foci accumulation) that result from the
20 mM DhL treatment may allow the improved handling of DNA
lesions, more accurate but slower transitions through the S and
G2/M phase (Figs. 4 and 5) and the final accumulation of cells in a
G1 phase senescence equilibrium (Fig. 7). Collectively, our
findings indicate that the accumulation of DhL-triggered DNA
lesions activates apoptotic or senescence responses that greatly
impair both short- and long-term proliferation potential (Figs. 1
and 5D).
DhL Triggers Cellular Senescence and Apoptosis in a
Concentration-dependent Manner
We have presented multiple lines of evidence that DhL causes
apoptosis and senescence in HeLa and HCT116 cells. DhL at a
concentration of 30 mM specifically increased the sub-G1 phase
population (Figs. 2A, B and S2A, B), the amount of TUNEL
positive (Fig. 2C,) and Annexin V positive cells (Figs. 2D), without
stopping the cell cycle. In contrast, 20 mM DhL triggered cell cycle
accumulation in the G1 phase (Figs. S2A, B and 5A, B) of cells that
had lower levels of broken DNA (Fig. 3A, B, C) and that
accumulated senescence markers (Fig. 7A, B, C, D). Although it is
tempting to interpret the nature of this sharp concentration-
dependent choice between apoptosis and senescence, the relevance
of our findings relies on the capacity of DhL to display strategies
against cancer cell proliferation in an additive fashion. In studies of
HCT116 cells the sensitivity to DhL appears to be higher than in
HeLa cells. DhL at a concentration of 10 mM was sufficient to
promote p53-dependent senescence (Fig. S4B), in agreement with
previous demonstrations of the role of p53 activation in cellular
choices of a senescence pathway [48]. Other p53-independent
signals may also contribute to the anti-proliferative effect of higher
DhL concentrations (Fig. 6B lower panels, 20 mM DhL treatment;
note the reduced difference between the numbers of p53-positive
vs. -negative cells). DhL may therefore function in cells of differing
genetic backgrounds, including p53-negative cells, triggering
senescence or apoptosis in a manner that depends on both the
cell type and the concentration of DhL used. This concept is
relevant to the treatment of solid tumors in which access of
different compounds to the tumor tissue may be limited by the
three-dimensional structure of the tumor mass. If DhL is validated
as a tumor-targeting agent, the treatment dose and time frame (see
Fig. 7E) may be parameters that can be effectively modulated to
reduce collateral damaging effects in the clinic.
The Mechanism of Action of DhL in Cancer Cell
Treatment
The mechanism of action of SLs remains poorly understood.
The biological activities of these compounds have been attributed
to various factors, including alkylating center reactivity, side
chains, lipophilicity, and molecular or electrical features [2].
Thapsigargin, an SL compound that is currently being evaluated
in phase I clinical trials, induces apoptosis via cytoplasmic signals
that involve sarco/endoplasmic reticulum calcium ATPase
(SERCA) pump inhibition and the release of cytochrome c from
mitochondria [13]. DhL is an SL that also belongs to the
guaianolide group and has the same carbon-cyclic skeleton as
thapsigargin; however, we found that the molecular pathways that
are activated by DhL treatment are not restricted to the cytoplasm.
The increase in phosphorylated ATM, and the formation of
cH2AX and 53BP1 foci strongly suggest that the signals that
generated DDR markers in the nucleus may be a trigger for
apoptotic and senescence programs; the latter comprise an
important anticancer process that has not been previously
associated with SL treatment. We believe that it is possible to
chemically dissect the biological anti-proliferative activities of
DhL. Although the anticancer activity of SLs of the guaianolide
group has been attributed to the alpha, beta-unsaturated carbonyl
group and its alkylating activity [11], we showed that a DhL with
inactivated alpha-methylene lactone function (2H-DhL) affected
the proliferation but not the viability of cells, suggesting that cell
cycle arrest and cytotoxicity are mediated by different cellular
targets of DhL [49].
Two important findings of the present study are the previously
undescribed link between SLs, markers of DDR, and p53-
dependent induced senescence and the fact that the degree of
senescence or apoptosis induced by DhL is dose-dependent. There
are clear potential advantages in the use of DhL for tumor
treatment. Low doses of DhL can cause permanent cell cycle arrest
in cancer cells that have damaged DNA, while higher doses can
eradicate tumor cells by apoptosis.
Supporting Information
Figure S1 (A) The chemical structure of dehydroleuco-
dine. (B) Unsynchronized WI-38 and WI-38 VA cells were
treated with 0, 5, 10 or 20 mM DhL for 72 h and counted every
24 h. Data are expressed as the mean 6 SEM of 3 independent
experiments, * p#0.05 for WI-38 vs. WI-38 VA cells.
(TIF)
Figure S2 20 mM DhL induces cell cycle arrest whereas
30 mM DhL induces apoptosis. Unsynchronized (A) and
synchronized (B) HeLa cells were treated with 0, 20, or 30 mM
DhL for 24 or 48 h. DNA content was assessed by flow cytometry.
Representative DNA distributions from 1 experiment are shown.
The hypodiploid picks are indicated by arrows. (C) Representative
panels for Anexin V positive HeLa cells (bright cells) treated with
0, 20, or 30 mM DhL for 48 or 72 h.
(TIF)
Figure S3 DNA damage might result from DhL treat-
ment. (A) Unsynchronized HeLa cells were treated with 20 mM
DhL for the indicated time points or espouse to UV radiation by
4 h, and the levels of p-ATM accumulation were assayed by
immunoblot. b-actin was employed as a loading control. (B and C)
Unsynchronized HeLa cells were treated with 0, 20, or 30 mM
DhL for 48 h. Samples were stained with DAPI to visualize the
nuclei and specific antibodies for cH2AX (B) and 53BP1 (C) were
used. Representative fields are shown. Insets are magnifications of
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the areas indicated by boxes in the top row. Bar: 10 mm. The
images shown are representative of 3 independent experiments.
(TIF)
Figure S4 DhL-induced senescence is higher in p53+/+
than in p532/2 cells. (A) HCT116 p53+/+ and p532/2 cells
treated with 20 or 30 mM DhL were lysed at the indicated time
points and used to determine p53 and p21 levels by immunoblot.
The immunoblots shown are representative of 3 independent
experiments with similar result. (B) HCT116 p53+/+ and p532/
2 cells treated with 10 mM DhL for 48 h were used to determine
SA-b-Gal activity at pH 6 in situ. Left: cells stained for SA-b-Gal
and examined by bright field microscopy. Bar: 50 mm. Right:
percentages SA-b-Gal-positive cells. Data represent the mean 6
SEM of 2 experiments. * p#0.05, ** p#0.01, *** p#0.001 vs.
control group (0 mM). ## p#0.01 for HCT116 p53+/+ vs.
HCT116 p532/2 cells.
(TIF)
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